|Description||Cilastatin sodium is the sodium salt of cilastatin, which is a dipeptidase inhibitor of renal enzyme dehydropeptidase-I and leukotriene D4 peptidase. It inhibits metabolism of LTD4 to LTE4 and the hydrolysis of β-lactam antibiotics. It reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. It can be combined intravenously with imipenem in order to protect it from dehydropeptidase. It suppresses both host and target metabolism of the broad-spectrum antibiotic imipenem, improving its efficacy. It usually confers antibiotic resistance to certain bacteria because itself does not have antibiotic activity. It has nephroprotective effects.|
|B0084-077802||1 g||$550||In stock|
|Purity||≥99% by HPLC|
|Synonyms||L 642957; MK 791; L642957; MK791; L-642957; MK-791; [R-[R*,S*-(Z)]]-7-[(2-Amino-2-carboxyethyl)thio]-2-[[(2,2-dimethylcyclopropyl)carbonyl]amino]-2-heptenoic Acid Monosodium Salt; (2Z)-7-[[(2R)-2-Amino-2-carboxyethyl]thio]-2-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]amino]-2-heptenoic Acid Sodium Salt; sodium S-((Z)-6-carboxy-6-((S)-2,2-dimethylcyclopropane-1-carboxamido)hex-5-en-1-yl)-L-cysteinate|
Cinalukast is a selective Leukotriene D4 receptor antagonist originated by Roche and IC 50 value is 6.4 nM. Cinalukast inhibits the actions of Leukotriene D4 at...
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
LY-25648 is a leukotriene B4 antagonist.
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
MK-571 sodium salt hydrate
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
Acebilustat, formerly known as ZK322, is an oral anti-inflammatory designed to reduce the production of leukotriene B4 (LTB4),.
LY 292728, an oxoxanthene derivative, has been found to be a leukotriene B4 receptor antagonist that has once been studied as an antiasthmatic agent.